Combination incretin therapies Next-generation pharmacological treatments for obesity include combinations of GLP-1 receptor agonists with other enteropancreatic hormones (such as GIP, glucagon and amylin)
Mitigation: taper dose gradually, avoid stopping DSIP during periods of known high stress (project deadlines, travel, illness), and implement behavioral sleep hygiene during the taper to scaffold sleep quality as the peptide signal diminishes
It is an FDA-approved topical and oral medication, and it works for many patients
Many do not, because the compound quality is unverified, the dose is based on internet research rather than clinical assessment, and there is no baseline, no follow-up, and no protocol adjustment based on individual response